The client faced a complex fourth re‑submission to the Scottish Medicines Consortium, with gaps in adverse event evidence, adherence‑related outcomes, […]
Client Challenge The client faced an unclear approval landscape, which led to delays in decision-making around market access activities. At
Author: Florian Stieglitz, Market Access Consultant Faced with increasing complexity from internal organisational restructuring that created frictions around decision making
Author: Florian Stieglitz, Market Access Consultant The Kintiga team supported our client to gain a clearer understanding of the legal
Faced with regulatory rejection in Europe despite FDA approval, a US-based pharmaceutical company turned to Kintiga to reframe its product’s
Client Challenge Six years after initial approval, the German branch of the pharmaceutical company was surprised by an indication expansion
Client Challenge The company’s German organisation, inexperienced with AMNOG and understaffed for the process, had great difficulty explaining the importance
Client Challenge The pharmaceutical company engaged us to develop a negotiation strategy for a product that has been on the
Client Challenge When innovative drugs are used in hospital treatment after their approval, the question often arises as to how drug
Client Challenge Innovative gene therapies can offer patients with serious illnesses an alternative treatment option. Unfortunately, they also pose risks
